Last reviewed: May 29, 2026
Last updated: May 29, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell that drives energy metabolism, DNA repair, and stress-response pathways. Studies suggest NAD+ levels decline approximately 50% between age 20 and 60, potentially affecting mitochondrial function and cellular resilience.
For patients exploring longevity strategies, understanding NAD+ alongside genetic predispositions offers a more complete picture. PlexusDx precision wellness approach considers how individual genetic variants in metabolic pathways—including FTO and MC4R—may influence energy metabolism, informing personalized recommendations.
NAD+ and Cellular Energy: The Fundamental Mechanism
NAD+ functions as an electron carrier in glycolysis, the citric acid cycle, and the electron transport chain. Without adequate NAD+, mitochondria cannot efficiently convert glucose and fats into ATP, the cell's primary energy currency. This mechanism underpins NAD+'s relevance to metabolic health and fatigue.
Research in aging models demonstrates that restoring NAD+ levels activates sirtuins and PARPs—protein families that regulate DNA repair, inflammation, and cellular senescence. Animal studies show NAD+ supplementation may support mitochondrial biogenesis, though human clinical evidence remains limited and should be interpreted cautiously.
Evidence-Based NAD+ Applications and Clinical Context
NAD+ is studied across multiple health domains. Below is a framework summarizing current research areas, their evidence status, and typical patient populations where providers may consider NAD+ as part of a comprehensive strategy.
| Application Area |
Clinical Evidence Level |
Typical Population |
Key Mechanism |
| Mitochondrial function and fatigue |
Preclinical + limited human trials |
Post-viral fatigue, chronic conditions |
ATP restoration via oxidative phosphorylation |
| Cognitive aging and neuroprotection |
Animal models + small observational studies |
Age-related cognitive decline, neurodegenerative risk |
Sirtuin activation, neuroinflammation reduction |
| Metabolic health and insulin sensitivity |
Cell studies + rodent models |
Prediabetes, metabolic syndrome, insulin resistance |
SIRT1 activation, improved mitochondrial metabolism |
| DNA repair and radiation exposure |
Preclinical evidence |
Post-chemotherapy, occupational exposure |
PARP activation, homologous recombination repair |
NAD+ Status, Biomarkers, and Personalization Strategy
Baseline NAD+ levels vary widely between individuals due to age, genetics, diet, and lifestyle. Direct NAD+ measurement remains expensive and not standardized in clinical practice, limiting its utility as a routine screening tool. However, indirect biomarkers—lactate, pyruvate, mitochondrial function tests—can provide context for provider decision-making.
Genetic variants in metabolic pathways influence how efficiently individuals convert precursors (like NMN or NR) into NAD+. For example, variations in genes regulating NAD+ synthesis enzymes may predict responsiveness to supplementation. Understanding your genetic background can help providers tailor dosing and timing recommendations.
Safety Considerations and Provider Guidance
NAD+ precursors (NMN, NR) are generally well-tolerated in short-term studies, though long-term safety data in humans remains limited. Individuals on chemotherapy or with cancer history should consult oncologists before use, as elevated NAD+ may theoretically support cancer cell energy demands. Pregnant and nursing populations should avoid supplementation pending further evidence.
A qualified healthcare provider should evaluate baseline health, medications, and personal risk factors before recommending NAD+-boosting strategies. NAD+ therapy is not a replacement for established interventions like exercise, sleep optimization, and metabolic assessment. Combining NAD+ with a comprehensive longevity plan yields the strongest outcomes.
How PlexusDx Supports a More Personalized Approach
PlexusDx's Precision Peptide Genetic Test may help provide context on metabolic pathways relevant to NAD+ function. Variants in FTO (fat mass and obesity-associated gene) and MC4R (melanocortin-4 receptor) influence baseline metabolic rate and energy utilization efficiency. These insights, interpreted with a qualified provider, can support decisions about whether NAD+ supplementation aligns with your genetic predispositions.
The Precision Peptide Genetic Test reveals predispositions in metabolic and peptide signaling pathways—not exact NAD+ response. Individuals with genetic variants associated with lower metabolic efficiency may benefit from comprehensive evaluation including NAD+ status, mitochondrial markers, and energy metabolism assessment. Genetic context should always be combined with clinical evaluation and biomarker data.
Understanding your metabolic genetic profile can support a more informed conversation with your provider about NAD+ as part of a precision longevity strategy. Rather than assuming one-size-fits-all supplementation, providers can use genetic and biomarker insights to design individualized energy-optimization protocols. PlexusDx genetic testing costs $99 as an add-on or $298 standalone.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $179-$229/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is NAD+ and why does it decline with age?
NAD+ is a coenzyme essential for cellular energy and DNA repair. It declines roughly 50% from age 20 to 60 due to increased consumption by repair enzymes, reduced synthesis, and accumulated mitochondrial stress. This decline correlates with aging-related fatigue and metabolic shifts.
What evidence supports NAD+ for longevity and metabolic health?
Animal studies show NAD+ boosting improves mitochondrial function and lifespan. Human trials remain limited but suggest potential for metabolic markers and fatigue. Results are modest and require large, controlled studies before definitive clinical recommendations can be made.
How can I assess my NAD+ status before considering supplementation?
Direct NAD+ testing is expensive and not standardized clinically. Providers may evaluate indirect markers like lactate, pyruvate, and mitochondrial function tests. Comprehensive metabolic and energy assessment, combined with genetic predisposition data, supports better-informed decisions.
Are NAD+ precursors like NMN and NR safe for long-term use?
Short-term safety appears reasonable in clinical trials. Long-term human safety data is limited. Individuals with cancer history, on chemotherapy, or pregnant should avoid use pending further evidence. Always consult a provider before starting NAD+ supplementation.
How does genetic testing relate to NAD+ metabolism and supplementation?
PlexusDx Precision Peptide Genetic Test reveals predispositions in metabolic pathways like FTO and MC4R that influence energy utilization efficiency. These insights may help provide context for personalized NAD+ and longevity strategies, but genetics does not predict exact supplementation response and must be interpreted with a qualified provider.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Sermorelin Benefits: Evidence-Based Expectations and Clinical Considerations
How To Get Methylene Blue: Clinical Evidence and Provider-Led Access